Diabetes & Metabolism Journal

Jin-Woo Kim (Kim JW)

3 Articles

Covid-19
The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea: Mi Kyung Kim, Jae-Han Jeon, Sung-Woo Kim, Jun Sung Moon, Nan Hee Cho, Eugene Han, Ji Hong You, Ji Yeon Lee, Miri Hyun, Jae Seok Park, Yong Shik Kwon, Yeon-Kyung Choi, Ki Tae Kwon, Shin Yup Lee, Eon Ju Jeon, Jin-Woo Kim, Hyo-Lim Hong, Hyun Hee Kwon, Chi Young Jung, Yin Young Lee, Eunyeoung Ha, Seung Min Chung, Jian Hur, June Hong Ahn, Na-young Kim, Shin-Woo Kim, Hyun Ha Chang, Yong Hoon Lee, Jaehee Lee, Keun-Gyu Park, Hyun Ah Kim, Ji-Hyun Lee; Diabetes Metab J. 2020;44(4):602-613. Published online August 12, 2020; DOI: https://doi.org/10.4093/dmj.2020.0146

14,572 View
218 Download
71 Web of Science
83 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Coronavirus disease 2019 (COVID-19) is a global pandemic that had affected more than eight million people worldwide by June 2020. Given the importance of the presence of diabetes mellitus (DM) for host immunity, we retrospectively evaluated the clinical characteristics and outcomes of moderate-to-severe COVID-19 in patients with diabetes.

Methods

We conducted a multi-center observational study of 1,082 adult inpatients (aged ≥18 years) who were admitted to one of five university hospitals in Daegu because of the severity of their COVID-19-related disease. The demographic, laboratory, and radiologic findings, and the mortality, prevalence of severe disease, and duration of quarantine were compared between patients with and without DM. In addition, 1:1 propensity score (PS)-matching was conducted with the DM group.

Results

Compared with the non-DM group (n=847), patients with DM (n=235) were older, exhibited higher mortality, and required more intensive care. Even after PS-matching, patients with DM exhibited more severe disease, and DM remained a prognostic factor for higher mortality (hazard ratio, 2.40; 95% confidence interval, 1.38 to 4.15). Subgroup analysis revealed that the presence of DM was associated with higher mortality, especially in older people (≥70 years old). Prior use of a dipeptidyl peptidase-4 inhibitor or a renin-angiotensin system inhibitor did not affect mortality or the clinical severity of the disease.

Conclusion

DM is a significant risk factor for COVID-19 severity and mortality. Our findings imply that COVID-19 patients with DM, especially if elderly, require special attention and prompt intensive care.

Citations

Citations to this article as recorded by

Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
Carmen Tisch, Eleni Xourgia, Aristomenis Exadaktylos, Mairi Ziaka
Endocrine.2024; 85(2): 660. CrossRef
Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, Dorota Bednarska-Chabowska, Joanna Adamiec-Mroczek, Adrian Doroszko, Małgorzata Trocha, Krzysztof Kujawa, Agnieszka Matera-Witkiewicz, Edwin Kuźnik, Paweł Lubieniecki, Marcin Madziarski
Biomedicines.2024; 12(3): 605. CrossRef
Prognostic Value of Hyperglycemia and Insulin Resistance Among Patients with Confirmed COVID-19 Infections at Admission to the Alexandria Fever Hospital, Egypt
Fathy Z. Alsewy, Magdy H. Megallaa, Salma A. Imbaby, Huda M. Zidan, Heba S. Kassab, Mai H. Badrah
Metabolic Syndrome and Related Disorders.2024; 22(7): 551. CrossRef
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, Jian-Bo Zhou, Chao Zhang
Therapeutic Innovation & Regulatory Science.2024; 58(4): 773. CrossRef
The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
F1000Research.2024; 11: 729. CrossRef
The therapeutic potential of the use of gliclazide MV in combination with COVID-19 and type 2 diabetes mellitus
D. V. Belikina, T. A. Nekrasova, L. G. Strongin, E. M. Durygina, M. Yu. Rodina
FOCUS. Endocrinology.2024; 5(1): 20. CrossRef
Research status and hotspots in the field of endoplasmic reticulum stress and liver disease: A bibliometric study
Ruiyu Wang, Shu Huang, Ping Wang, Xiaowei Tang, Huan Xu, Wei Zhang, Lei Shi, Xiaolin Zhong, Muhan Lü, Xian Zhou, Xiaomin Shi
Medicine.2024; 103(22): e38450. CrossRef
The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
F1000Research.2024; 11: 729. CrossRef
The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
F1000Research.2024; 11: 729. CrossRef
The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
F1000Research.2024; 11: 729. CrossRef
The relationship of age, sex and prothrombin time related to the severity of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
F1000Research.2024; 11: 729. CrossRef
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
Diabetes Research and Clinical Practice.2023; 195: 110205. CrossRef
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, Philipp Linnerz, Kalliopi Pafili, Oliver Kuss, Christian Herder, Manuela Neuenschwander, Janett Barbaresko, Michael Roden
Diabetologia.2023; 66(8): 1395. CrossRef
Factors influencing the severity of COVID-19 course for patients with diabetes mellitus in tashkent: a retrospective cohort study
A. V. Alieva, A. A. Djalilov, F. A. Khaydarova, A. V. Alimov, D. Z. Khalilova, V. A. Talenova, N. U. Alimova, M. D. Aripova, A. S. Sadikova
Obesity and metabolism.2023; 20(2): 92. CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef
Epidemiological features and consequences of COVID‐19 in patients with and without gastrointestinal symptoms in southwestern Iran. A retrospective observational study
Habibollah Azarbakhsh, Leila Moftakhar, Aliasghar Valipour, Alireza Mirahmadizadeh, Hekmat Allah Moradi, Elahe Piraee
Health Science Reports.2023;[Epub] CrossRef
The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
Yun-Ting Huang, Andrew Steptoe, Riyaz S. Patel, Esme Fuller Thomson, Dorina Cadar
Gerontology.2023; 69(10): 1200. CrossRef
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, Huimei Zhang, Guangbo Qu, Yue Chen, Ce Cheng, Eric L. Chen, Mubashir Ayaz Ahmed, Keun Young Kim, Raveena Manem, Mengshi Chen, Zhichun Guo, Hongru Yang, Yue Yan, Qin Zhou
Archives of Medical Research.2022; 53(2): 186. CrossRef
Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling
Diabetes & Metabolism.2022; 48(1): 101307. CrossRef
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary Care Diabetes.2022; 16(1): 162. CrossRef
Prevalence and impact of diabetes in hospitalized COVID‐19 patients: A systematic review and meta‐analysis
Sian A. Bradley, Maciej Banach, Negman Alvarado, Ivica Smokovski, Sonu M. M. Bhaskar
Journal of Diabetes.2022; 14(2): 144. CrossRef
Interplay between Inflammaging, Frailty and Nutrition in Covid-19: Preventive and Adjuvant Treatment Perspectives
A. Padilha de Lima, M. Macedo Rogero, T. Araujo Viel, H.M. Garay-Malpartida, I. Aprahamian, Sandra Maria Lima Ribeiro
The Journal of nutrition, health and aging.2022; 26(1): 67. CrossRef
Increase in blood glucose level and incidence of diabetic ketoacidosis in children with type 1 diabetes mellitus in the Daegu-Gyeongbuk area during the coronavirus disease 2019 (COVID-19) pandemic: a retrospective cross-sectional study
Mi Seon Lee, Rosie Lee, Cheol Woo Ko, Jung Eun Moon
Journal of Yeungnam Medical Science.2022; 39(1): 46. CrossRef
Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network
Qian Gao, Wenjun Zhang, Tingting Li, Guojun Yang, Wei Zhu, Naijun Chen, Huawei Jin
Scientific Reports.2022;[Epub] CrossRef
Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation
Afnan Alshnbari, Iskandar Idris
Current Medical Research and Opinion.2022; 38(3): 357. CrossRef
Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
Li-Min Zhao, Xie-Hui Chen, Mei Qiu
Frontiers in Endocrinology.2022;[Epub] CrossRef
COVID-19 and Diabetes
Awadhesh Kumar Singh, Kamlesh Khunti
Annual Review of Medicine.2022; 73(1): 129. CrossRef
The enzymes in COVID-19: A review
Maria Helena Menezes Estevam Alves, Layla Carvalho Mahnke, Tifany Cerqueira Macedo, Thais Ketinly dos Santos Silva, Luiz Bezerra Carvalho Junior
Biochimie.2022; 197: 38. CrossRef
IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
Adnan A. Zainal, Marwan M. Merkhan
Military Medical Science Letters.2022; 91(2): 140. CrossRef
Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
Adithan Ganesh, Michael D. Randall
British Journal of Clinical Pharmacology.2022; 88(6): 2642. CrossRef
Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin
Clifford J. Bailey, Mike Gwilt
Frontiers in Pharmacology.2022;[Epub] CrossRef
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
Evangelia Tzeravini, Eleftherios Stratigakos, Chris Siafarikas, Anastasios Tentolouris, Nikolaos Tentolouris
Frontiers in Clinical Diabetes and Healthcare.2022;[Epub] CrossRef
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, Dang Khanh Ngan Ho, Hung-Yuan Li, Chia-Yuan Lin, Hsiao-Yean Chiu, Yang-Ching Chen
Metabolism.2022; 131: 155196. CrossRef
Glucose-Lowering Agents and COVID-19
Ah Reum Khang
The Journal of Korean Diabetes.2022; 23(1): 1. CrossRef
Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
Endocrinology, Diabetes & Metabolism.2022;[Epub] CrossRef
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, Mohammad Arshad, Mengjun Dai
Frontiers in Endocrinology.2022;[Epub] CrossRef
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
Journal of the American Heart Association.2022;[Epub] CrossRef
Diabetes and SARS-CoV-2–Is There a Mutual Connection?
Anna P. Jedrzejak, Edyta K. Urbaniak, Jadwiga A. Wasko, Natalia Ziojla, Malgorzata Borowiak
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
The relationship of age, sex and prothrombin time related to the severity and mortality of COVID-19 patients with diabetes mellitus: a systematic review and meta analysis
Audrey Fabianisa Mirza, Ceria Halim, Mutiara Indah Sari
F1000Research.2022; 11: 729. CrossRef
Are lipid ratios and triglyceride-glucose index associated with critical care outcomes in COVID-19 patients?
Marzieh Rohani-Rasaf, Kosar Mirjalili, Akram Vatannejad, Maryam Teimouri, Xiao-Feng Yang
PLOS ONE.2022; 17(8): e0272000. CrossRef
Early glycaemic variability increases 28-day mortality and prolongs intensive care unit stay in critically ill patients with pneumonia
Seong Ho Kim, Ji Young Kim, Eun Song Kim, Il Rae Park, Eun Yeong Ha, Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
Annals of Medicine.2022; 54(1): 2724. CrossRef
Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
Niya Narayanan, Dukhabandhu Naik, Jayaprakash Sahoo, Sadishkumar Kamalanathan
World Journal of Virology.2022; 11(6): 399. CrossRef
Prevalencia de secuelas en pacientes con diabetes mellitus tipo 2 sobrevivientes al COVID-19
Gianela M. Cancino-Castillo, Miguel A. Tresierra-Ayala, Jorge L. Campos-Reyna, Jaime Rosales-Rimache
REVISTA MÉDICA VALLEJIANA/ Vallejian Medical Journal.2022; 11(2): 48. CrossRef
Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq
Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 33. CrossRef
Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, Anoop Misra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(1): 159. CrossRef
COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis
Mark Thomaz Ugliara Barone, Belinda Ngongo, Simone Bega Harnik, Lucas Xavier de Oliveira, Dániel Végh, Patrícia Vieira de Luca, Hermelinda Cordeiro Pedrosa, Franco Giraudo, Roque Cardona-Hernandez, Nayanjeet Chaudhury, Luiz Menna-Barreto
Diabetes Research and Clinical Practice.2021; 171: 108587. CrossRef
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
Chia Siang Kow, Syed Shahzad Hasan
Therapies.2021; 76(4): 361. CrossRef
Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
B. M. Bonora, A. Avogaro, G. P. Fadini
Journal of Endocrinological Investigation.2021; 44(7): 1379. CrossRef
Prognostic bioindicators in severe COVID-19 patients
L. Bergantini, E. Bargagli, M. d'Alessandro, R.M. Refini, P. Cameli, L. Galasso, C. Scapellato, F. Montagnani, S. Scolletta, F. Franchi, S. Valente, D. Bennett, G. Sebastiani, B. Frediani, F. Dotta
Cytokine.2021; 141: 155455. CrossRef
Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients
Leila Moftakhar, Parisa Moftakhar, Elahe Piraee, Haleh Ghaem, Aliasghar Valipour, Habibollah Azarbakhsh
International Journal of Diabetes in Developing Countries.2021; 41(3): 383. CrossRef
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
André J. Scheen
Diabetes & Metabolism.2021; 47(2): 101213. CrossRef
Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, Leila Ait Bachir, Ingrid Allix, Deborah Ancelle, Sara Barraud, Lyse Bordier, Aurélie Carlier, Nicolas Chevalier, Christine Coffin‐Boutreux, Emmanuel Cosson, Anne Dorange, O
Diabetes, Obesity and Metabolism.2021; 23(5): 1162. CrossRef
Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis
Rimesh Pal, Mainak Banerjee, Soham Mukherjee, Ranjitpal Singh Bhogal, Amanpreet Kaur, Sanjay K. Bhadada
Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882199648. CrossRef
Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, Giovanni Corrao, Franz H. Messerli
Journal of Hypertension.2021; 39(4): 784. CrossRef
Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis
Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Qingrong Sun, Yue Zhang, Xiaosheng Wang
Frontiers in Pharmacology.2021;[Epub] CrossRef
Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
Timotius Ivan Hariyanto, Andree Kurniawan
Journal of Diabetes & Metabolic Disorders.2021; 20(1): 543. CrossRef
Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis
Halla Kaminska, Lukasz Szarpak, Dariusz Kosior, Wojciech Wieczorek, Agnieszka Szarpak, Mahdi Al-Jeabory, Wladyslaw Gawel, Aleksandra Gasecka, Milosz J. Jaguszewski, Przemyslawa Jarosz-Chobot
Acta Diabetologica.2021; 58(8): 1101. CrossRef
Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, Henny Juliastuti, Eka Noneng Nawangsih, Arief Wibowo, Michael Anthonius Lim, Raymond Pranata
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(3): 777. CrossRef
Post-infection depressive, anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19
Flavia Ismael, João C.S. Bizario, Tatiane Battagin, Beatriz Zaramella, Fabio E. Leal, Julio Torales, Antonio Ventriglio, Megan E. Marziali, Silvia S. Martins, João M. Castaldelli-Maia
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2021; 111: 110341. CrossRef
Managing diabetes in diabetic patients with COVID: where do we start from?
Angelo Avogaro, Benedetta Bonora, Gian Paolo Fadini
Acta Diabetologica.2021; 58(11): 1441. CrossRef
Is diabetes mellitus a wrongdoer to COVID-19 severity?
Sanjib Sarkar, Dibyendu Das, Sawlang Borsingh Wann, Jatin Kalita, Prasenjit Manna
Diabetes Research and Clinical Practice.2021; 178: 108936. CrossRef
Dipeptidyl Peptidase 4 Inhibitor, an Update
Ju Hee Lee
The Journal of Korean Diabetes.2021; 22(2): 91. CrossRef
Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19
Zhenmu Jin, Mo Zheng, Jichan Shi, Xinchun Ye, Fang Cheng, Que-Lu Chen, Jianping Huang, Xian-Gao Jiang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
Anna R. Kahkoska, Trine Julie Abrahamsen, G. Caleb Alexander, Tellen D. Bennett, Christopher G. Chute, Melissa A. Haendel, Klara R. Klein, Hemalkumar Mehta, Joshua D. Miller, Richard A. Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse, Tim Q. Duong
Diabetes Care.2021; 44(7): 1564. CrossRef
The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus
Wenxing Yang, Xuehong Sun, Jun Zhang, Kui Zhang
Diabetes Research and Clinical Practice.2021; 178: 108977. CrossRef
Renin‐Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID‐19
Jordan Loader, Erik Lampa, Stefan Gustafsson, Thomas Cars, Johan Sundström
Journal of the American Heart Association.2021;[Epub] CrossRef
Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus
Ayça Elibol, Didem Eren, Macide Deniz Erdoğan, Merve Elmaağaç, Oguzhan Sıtkı Dizdar, İlhami Çelik, Ali İhsan Günal
Primary Care Diabetes.2021; 15(5): 806. CrossRef
Aging & COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors
Melina Farshbafnadi, Sara Kamali Zonouzi, Mohammadmahdi Sabahi, Mahsa Dolatshahi, Mohammad Hadi Aarabi
Experimental Gerontology.2021; 154: 111507. CrossRef
Classical and Counter-Regulatory Renin–Angiotensin System: Potential Key Roles in COVID-19 Pathophysiology
Moudhi Almutlaq, Abir Abdullah Alamro, Fayhan Alroqi, Tlili Barhoumi
CJC Open.2021; 3(8): 1060. CrossRef
Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
Yin Li, Xue Yang, Peijing Yan, Tong Sun, Zhi Zeng, Sheyu Li
Frontiers in Medicine.2021;[Epub] CrossRef
Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
Marina Treskova-Schwarzbach, Laura Haas, Sarah Reda, Antonia Pilic, Anna Borodova, Kasra Karimi, Judith Koch, Teresa Nygren, Stefan Scholz, Viktoria Schönfeld, Sabine Vygen-Bonnet, Ole Wichmann, Thomas Harder
BMC Medicine.2021;[Epub] CrossRef
COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
Endocrinology and Metabolism.2021; 36(4): 757. CrossRef
High Fibrosis-4 Index Is Related with Worse Clinical Outcome in Patients with Coronavirus Disease 2019 and Diabetes Mellitus: A Multicenter Observational Study
Sung-Woo Kim, Jae-Han Jeon, Jun Sung Moon, Mi Kyung Kim
Endocrinology and Metabolism.2021; 36(4): 800. CrossRef
Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
Chengxia Kan, Yang Zhang, Fang Han, Qian Xu, Tongtong Ye, Ningning Hou, Xiaodong Sun
Frontiers in Endocrinology.2021;[Epub] CrossRef
Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-
E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, A. R. Vaisberg, A. S.
Kardiologiia.2021; 61(9): 20. CrossRef
Association of clinical characteristics, antidiabetic and cardiovascular agents with diabetes mellitus and COVID-19: a 7-month follow-up cohort study
Marzieh Pazoki, Fatemeh Chichagi, Azar Hadadi, Samira Kafan, Mahnaz Montazeri, Sina Kazemian, Arya Aminorroaya, Mehdi Ebrahimi, Haleh Ashraf, Mojgan Mirabdolhagh Hazaveh, Mohammad Reza Khajavi, Reza Shariat Moharari, Seyed Hamidreza Sharifnia, Shahrokh Ka
Journal of Diabetes & Metabolic Disorders.2021; 20(2): 1545. CrossRef
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
Frontiers in Endocrinology.2021;[Epub] CrossRef
Impact of Diabetes on COVID-19 Mortality and Hospital Outcomes, a Global Perspective: An ONTOP Systematic Review and Meta-Analysis
Stavroula Kastora, Manisha Patel, Ben Carter, Mirela Delibegovic, Phyo Kyaw Myint
SSRN Electronic Journal .2021;[Epub] CrossRef
Decision Trees: Predictions of Global Vulnerability to Coronavirus Outbreaks
Moacir José da Silva
SSRN Electronic Journal .2020;[Epub] CrossRef
The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
Liman Luo, Menglu Fu, Yuanyuan Li, Shuiqing Hu, Jinlan Luo, Zhihui Chen, Jing Yu, Wenhua Li, Ruolan Dong, Yan Yang, Ling Tu, Xizhen Xu
Clinical Cardiology.2020; 43(12): 1478. CrossRef
The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
Antonia Anna Lukito, Raymond Pranata, Joshua Henrina, Michael Anthonius Lim, Sherly Lawrensia, Ketut Suastika
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(6): 2177. CrossRef
Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data
Seon-Rye Kim, Seoul-Hee Nam, Yu-Rin Kim
International Journal of Environmental Research and Public Health.2020; 17(23): 8847. CrossRef
Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea
Ji Hong You, Sang Ah Lee, Sung-Youn Chun, Sun Ok Song, Byung-Wan Lee, Dae Jung Kim, Edward J. Boyko
Endocrinology and Metabolism.2020; 35(4): 901. CrossRef

Autoimmune Hypoglycemia in a Patient with Characterization of Insulin Receptor Autoantibodies: Suk Chon, Moon Chan Choi, Yun Jung Lee, You Cheol Hwang, In-Kyung Jeong, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-Taek Woo, Sung-Woon Kim, Jin-Woo Kim, Young Seol Kim; Diabetes Metab J. 2011;35(1):80-85. Published online February 28, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.1.80

5,992 View
52 Download
19 Crossref

Abstract PDF PubReader

Background

Type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor that results in severe hyperglycemia and acanthosis nigricans. However, the mechanisms by which these autoantibodies induce hypoglycemia are largely unknown. In this paper, we report the case of patient with type B insulin resistance syndrome who presented with frequent severe fasting hypoglycemia and acanthosis nigricans.

Methods

To evaluate the mechanism of hypoglycemia, we measured the inhibition of insulin binding to erythrocytes and IM9 lymphocytes in a sample of the patient's dialyzed serum before and after immunosuppressive therapy.

Results

In the patient's pre-treatment serum IgG, the binding of ¹²⁵I-insulin to erythrocytes was markedly inhibited in a dose-dependent manner until the cold insulin level reached 10^-9 mol/L. We also observed dose-dependent inhibition of insulin binding to IM9 lymphocytes, which reached approximately 82% inhibition and persisted even when diluted 1:20. After treatment with glucocorticoids, insulin-erythrocyte binding activity returned to between 70% and 80% of normal, while the inhibition of insulin-lymphocyte binding was reduced by 17%.

Conclusion

We treated a patient with type B insulin resistance syndrome showing recurrent fasting hypoglycemia with steroids and azathioprine. We characterized the patient's insulin receptor antibodies by measuring the inhibition of insulin binding.

Citations

Citations to this article as recorded by

Systematic Review—Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin
Natasha Brown, Marianne S Elston
The Journal of Clinical Endocrinology & Metabolism.2024; 109(4): 936. CrossRef
Type B insulin resistance syndrome: a systematic review
Luizianne Mariano Martins, Virgínia Oliveira Fernandes, Manuela Montenegro Dias de Carvalho, Daniel Duarte Gadelha, Paulo Cruz de Queiroz, Renan Magalhães Montenegro
Archives of Endocrinology and Metabolism.2020;[Epub] CrossRef
Autoimmune hypoglycemia
Marina Y. Yukina, Diana A. Davtyan, Ekaterina A. Troshina, Nurana F. Nuralieva
Obesity and metabolism.2018; 15(3): 9. CrossRef
Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
Simon A. Hinke, Anne M. Cieniewicz, Thomas Kirchner, Katharine D'Aquino, Rupesh Nanjunda, Jason Aligo, Robert Perkinson, Philip Cooper, Ken Boayke, Mark L. Chiu, Steve Jarantow, Eilyn R. Lacy, Yin Liang, Dana L. Johnson, Jean M. Whaley, Russell B. Lingham
Molecular Metabolism.2018; 10: 87. CrossRef
Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study
Joanna Klubo-Gwiezdzinska, Maria Lange, Elaine Cochran, Robert K. Semple, Cornelia Gewert, Rebecca J. Brown, Phillip Gorden
Diabetes Care.2018; 41(11): 2353. CrossRef
Hypoinsulinemic Hypoglycemia Followed By The Onset Of Severe Insulin Resistance With Hyperglycemia And Circulating Anti-Insulin Receptor Antibodies In A Patient Suffering Systemic Lupus Erythematosus: A Case Report And Literature Review
Guillermo Martínez de Pinillos, Mariana Tomé, María M. Viloria, Joaquín Bobillo, María V. Cózar
AACE Clinical Case Reports.2017; 3(3): e284. CrossRef
The treatment of hyperinsulinemic hypoglycaemia in adults: an update
M. V. Davi′, A. Pia, V. Guarnotta, G. Pizza, A. Colao, A. Faggiano
Journal of Endocrinological Investigation.2017; 40(1): 9. CrossRef
Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report
Lavanya Viswanathan, Imali Sirisena
Journal of the Endocrine Society.2017; 1(12): 1435. CrossRef
反復する低血糖発作を契機に発見されたインスリン受容体異常症B型の1例(A case of type B insulin resistance presenting as recurrent hypoglycemia)
杉本龍 (Ryu Sugimoto), 髙木誠 (Makoto Takaki), 前原潤一 (Junichi Maehara), 具嶋泰弘 (Yasuhiro Gushima)
Nihon Kyukyu Igakukai Zasshi: Journal of Japanese Association for Acute Medicine.2017; 28(3): 100. CrossRef
Type B insulin resistance syndrome
Devina L. Willard, Mary Stevenson, Devin Steenkamp
Current Opinion in Endocrinology, Diabetes & Obesity.2016; 23(4): 318. CrossRef
Antibody-Mediated Insulin Resistance: When Insulin and Insulin Receptor Act as Autoantigens in Humans
Christelle Liminet, Julien Vouillarmet, Karim Chikh, Emmanuel Disse
Canadian Journal of Diabetes.2016; 40(5): 462. CrossRef
The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis
Adel A.A. Ismail
Clinical Chemistry and Laboratory Medicine (CCLM).2016; 54(11): 1715. CrossRef
Type B insulin-resistance syndrome presenting as autoimmune hypoglycemia, associated with systemic lupus erythematosus and interstitial lung disease
Seon Mee Kang, Heung Yong Jin, Kyung Ae Lee, Ji Hyun Park, Hong Sun Baek, Tae Sun Park
The Korean Journal of Internal Medicine.2013; 28(1): 98. CrossRef
Treatment of recurrent hypoglycemia with plasmapheresis and steroid in nondiabetic patient
Mustafa Kulaksızoglu, Mustafa Sait Gonen, Levent Kebapcilar, Fatih Sahin, Fatih Demirci, Ali Topcu
Transfusion and Apheresis Science.2013; 48(1): 11. CrossRef
A Case of Persistent Hypoglycemia: When to Think Outside the Box
Yogeswari Venugopal, Shireene Vethakkan, Sargunan Sockalingam, Raja Jasmin, Karen Choong
Clinical Diabetes.2013; 31(3): 130. CrossRef
The effect of hyperglycemia and hypoglycemia on glucose transport and expression of glucose transporters in human lymphocytes B and T: An in vitro study
Bożenna Oleszczak, Leszek Szablewski, Monika Pliszka
Diabetes Research and Clinical Practice.2012; 96(2): 170. CrossRef
The effect of glucose concentrations in the medium on expression of insulin receptors in human lymphocytes B and T: anin vitrostudy
Bożenna Oleszczak, Leszek Szablewski, Monika Pliszka
Journal of Receptors and Signal Transduction.2012; 32(5): 263. CrossRef
Fulminant Type 1 diabetes in a pregnant woman as an initial manifestation of the insulin autoimmune syndrome
H. S. Kim, T.‐Y. Lee, E. Y. Kim, J. H. Choi, S. Y. Kim, Y.‐C. Hwang, J.‐H. Kang, K. J. Ahn, H. Y. Chung, I.‐K. Jeong
Diabetic Medicine.2012; 29(10): 1335. CrossRef
A Case of the Type B Insulin Resistance Syndrome with Chronic Hepatitis B
Hyun Seok Choi, Byoung Ho Choi, Seok Hoo Jeong, Shung Han Choi, Dong Su Shin, Sei hyun Kim, Young Sil Eom, Sihoon Lee, Yeun Sun Kim, Ie Byung Park, Ki Young Lee
Endocrinology and Metabolism.2011; 26(4): 360. CrossRef

The Changes in Early Phase Insulin Secretion in Newly Diagnosed, Drug Naive Korean Prediabetes Subjects: Sang Youl Rhee, Joo Young Kim, Suk Chon, You Cheol Hwang, In Kyung Jeong, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-taek Woo, Sung Woon Kim, Jin-Woo Kim, Young Seol Kim; Korean Diabetes J. 2010;34(3):157-165. Published online June 30, 2010; DOI: https://doi.org/10.4093/kdj.2010.34.3.157

4,965 View
30 Download
15 Crossref

Abstract PDF PubReader

Background

There have been no systematic observations regarding changes in early phase insulin secretion among Korean prediabetes and early stage type 2 diabetes mellitus (T2DM) patients.

Methods

We conducted 75-g oral glucose tolerance tests (OGTT) in 873 subjects with suspected abnormal glucose tolerance. All subjects were diagnosed as having normal glucose tolerance (NGT), prediabetes (preDM), or T2DM according to the OGTT results and the insulin secretory and insulin resistance indices of each subject were calculated. Additionally, we analyzed the changes in early phase insulin secretion according to changes in fasting (Glc₀), post-prandial (Glc₁₂₀) glucose and HbA1c (A1c) levels.

Results

As compared to subjects with NGT, the insulin secretory indices of the preDM and T2DM subjects progressively declined, and the insulin resistance indices were progressively aggravated. Early phase insulin secretion decreased rapidly according to the increments of Glc₀, Glc₁₂₀ and A1c, and these changes were most prominent in the NGT stage. Compared to the control group, the early phase insulin secretion levels of the preDM or T2DM subjects were less than 50% when Glc₀ was over 100 mg/dL, Glc₁₂₀ was over 145 mg/dL, and A1c was over 5.8%.

Conclusion

This study suggests that progressive beta cell dysfunction in Koreans may be initiated and rapidly aggravated during the period generally designated as 'normal.'

Citations

Citations to this article as recorded by

Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study
Sang Youl Rhee, Suk Chon, Kyu Jeung Ahn, Jeong-Taek Woo
Diabetes & Metabolism Journal.2019; 43(1): 49. CrossRef
Differential role of insulin resistance and β-cell function in the development of prediabetes and diabetes in middle-aged and elderly Chinese population
Xueli Cai, Lili Xia, Yuesong Pan, Dian He, Huiping Zhu, Tiemin Wei, Yan He
Diabetology & Metabolic Syndrome.2019;[Epub] CrossRef
Effects of Primary Aldosteronism and Different Therapeutic Modalities on Glucose Metabolism
Mi Kyung Kwak, Jee Yang Lee, Beom-Jun Kim, Seung Hun Lee, Jung-Min Koh
Journal of Clinical Medicine.2019; 8(12): 2194. CrossRef
Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non‐alcoholic fatty liver disease
Yuya Seko, Yoshio Sumida, Saiyu Tanaka, Kojiroh Mori, Hiroyoshi Taketani, Hiroshi Ishiba, Tasuku Hara, Akira Okajima, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Kazuyuki Kanemasa, Kohichiroh Yasui, Shunsuke Imai, Keiji Shim
Hepatology Research.2018;[Epub] CrossRef
Longitudinal Changes in Insulin Resistance, Beta-Cell Function and Glucose Regulation Status in Prediabetes
Chul-Hee Kim, Hong-Kyu Kim, Eun-Hee Kim, Sung-Jin Bae, Jaewon Choe, Joong-Yeol Park
The American Journal of the Medical Sciences.2018; 355(1): 54. CrossRef
Prenatal Dexamethasone Exposure Programs the Development of the Pancreas and the Secretion of Insulin in Rats
Yu-Chieh Chen, Ying-Hua Huang, Jiunn-Ming Sheen, You-Lin Tain, Hong-Ren Yu, Chih-Cheng Chen, Miao-Meng Tiao, Ho-Chang Kuo, Li-Tung Huang
Pediatrics & Neonatology.2017; 58(2): 135. CrossRef
Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients
Jong-Dai Kim, Won-Young Lee
Endocrinology and Metabolism.2016; 31(3): 354. CrossRef
The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study
Jun Sung Moon, Kyoung Soo Ha, Ji Sung Yoon, Hyoung Woo Lee, Hyun Chul Lee, Kyu Chang Won
Acta Diabetologica.2014; 51(2): 277. CrossRef
Association of Obstructive Sleep Apnea and Glucose Metabolism in Subjects With or Without Obesity
Nan Hee Kim, Nam H. Cho, Chang-Ho Yun, Seung Ku Lee, Dae Wui Yoon, Hyun Joo Cho, Jae Hee Ahn, Ji A. Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Chol Shin
Diabetes Care.2013; 36(12): 3909. CrossRef
Relative contributions of insulin resistance and β‐cell dysfunction to the development of Type 2 diabetes in Koreans
C.‐H. Kim, H.‐K. Kim, E. H. Kim, S. J. Bae, J.‐Y. Park
Diabetic Medicine.2013; 30(9): 1075. CrossRef
Associations among Body Mass Index, Insulin Resistance, and Pancreatic β-Cell Function in Korean Patients with New-Onset Type 2 Diabetes
Jin Ook Chung, Dong Hyeok Cho, Dong Jin Chung, Min Young Chung
The Korean Journal of Internal Medicine.2012; 27(1): 66. CrossRef
High normal HbA1c levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon Hospital Health Management Center Study 8 (TOPICS 8)
Y. Heianza, Y. Arase, K. Fujihara, H. Tsuji, K. Saito, S. D. Hsieh, S. Kodama, H. Shimano, N. Yamada, S. Hara, H. Sone
Diabetic Medicine.2012; 29(10): 1285. CrossRef
The Prediabetic Period: Review of Clinical Aspects
Sang Youl Rhee, Jeong-Taek Woo
Diabetes & Metabolism Journal.2011; 35(2): 107. CrossRef
Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure
Y.-H. Lee, B.-W. Lee, S. W. Chun, B. S. Cha, H. C. Lee
International Journal of Clinical Practice.2011; 65(10): 1076. CrossRef
Early Insulin Secretory Dysfunction in Korean Prediabetic Subjects: Should We Change the Criteria for "Prediabetes?"
Chul-Hee Kim
Korean Diabetes Journal.2010; 34(3): 154. CrossRef

Author index